治疗强度用于心脏性休克的管理:STEMI与非STEMI之间的比较
Shashank S Sinha1, Mohit Pahuja2, Rachna Kataria3
1Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
JACC. Advances
|June 28, 2024
概括
心脏性休克并发症急性心肌梗塞 (AMI-CS) 的死亡率很高. 这项研究发现,ST段升高心肌梗塞相关心脏病性休克 (STEMI-CS) 和非ST段升高心肌梗塞心脏病性休克 (NSTEMI-CS) 的住院死亡率相似.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 心脏性休克是急性心肌梗塞 (AMI) 患者的重要死亡原因.
- 了解STEMI-CS和NSTEMI-CS之间的差异和相似之处对于改善患者的治疗结果至关重要.
研究的目的:
- 将STEMI-CS患者的临床特征,医院疗程和治疗策略与NSTEMI-CS患者进行比较.
- 确定影响这些患者群体住院死亡率的因素.
主要方法:
- 分析了17个中心1110名成年人AMI-CS入院的数据.
- 在STEMI-CS和NSTEMI-CS队列之间比较住院死亡率,临床特征以及医疗和器械疗法的使用.
主要成果:
- 住院死亡率为41%,STEMI-CS (43%) 和NSTEMI-CS (39%) 组之间类似.
- 患有医院外或医院内心脏骤停的患者的死亡率更高,特别是在NSTEMI-CS组.
- 结合药物和机械循环支持的早期使用率很低,但在住院期间在两组人群中显著增加.
结论:
- 尽管有先进的支持,STEMI-CS和NSTEMI-CS患者都面临高的住院死亡率.
- 需要进一步的研究,包括随机对照试验,以优化AMI-CS.的干预时间和序列.
更多相关视频
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
767
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
767
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Increased pulse rate
651
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
651


